Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse

Science Translational Medicine

Volumn 8, Issue 333, 2016, Pages

  Pu, Yang ^a,b   Xu, Meng ^c   Liang, Yong ^d   Yang, Kaiting ^d   Guo, Yajun ^a   Yang, Xuanming ^e   Fu, Yang Xin ^b,c,d  

^a SOUTH CHINA UNIVERSITY OF TECHNOLOGY   (China)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d INSTITUTE OF BIOPHYSICS   (China)

^e SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ABIRATERONE; ANDROGEN RECEPTOR ANTAGONIST; ANTINEOPLASTIC AGENT; BICUCULLINE; CPG; ENZALUTAMIDE; FLUTAMIDE; IMMUNOMODULATING AGENT; LEUPRORELIN; UNCLASSIFIED DRUG; ANDROGEN RECEPTOR;

ADAPTIVE IMMUNITY; ANDROGEN DEPRIVATION THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG MEGADOSE; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; MALE; MOUSE; NONHUMAN; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; T LYMPHOCYTE ACTIVATION; ANIMAL; C57BL MOUSE; DRUG EFFECTS; IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS; T LYMPHOCYTE; TUMOR CELL LINE; TUMOR RECURRENCE;

ANDROGEN RECEPTOR ANTAGONISTS; ANIMALS; CELL LINE, TUMOR; GAMMA-AMINOBUTYRIC ACID; IMMUNITY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MALE; MICE, INBRED C57BL; NEOPLASM RECURRENCE, LOCAL; ORCHIECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; T-LYMPHOCYTES;

EID: 84963589359     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aad5659     Document Type: Article

References (46)

1. B. Schurko, W. K. Oh, Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer. Nat. Clin. Pract. Oncol. 5, 506-507 (2008).
2. Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 355, 1491-1498 (2000).
3. R. M. Attar, C. H. Takimoto, M. M. Gottardis, Castration-resistant prostate cancer: Locking up the molecular escape routes. Clin. Cancer Res. 15, 3251-3255 (2009).
4. T. Douglas, P. Bonte, F. Focquaert, K. Devolder, S. Sterckx, Coercion, incarceration, and chemical castration: An argument from autonomy. J. Bioeth. Inq. 10, 393-405 (2013).
5. J. M. Kuhn, T. Billebaud, H. Navratil, A. Moulonguet, J. Fiet, P. Grise, J. F. Louis, P. Costa, J. M. Husson, R. Dahan, C. Bertagna, R. Edelstein, Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N. Engl. J. Med. 321, 413-418 (1989).
6. M. A. Perlmutter, H. Lepor, Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev. Urol. 9 (Suppl. 1), S3-S8 (2007).
7. F. Ricci, G. Buzzatti, A. Rubagotti, F. Boccardo, Safety of antiandrogen therapy for treating prostate cancer. Expert Opin. Drug Saf. 13, 1483-1499 (2014).
8. M. Cutolo, A. Sulli, S. Capellino, B. Villaggio, P. Montagna, B. Seriolo, R. H. Straub, Sex hormones influence on the immune system: Basic and clinical aspects in autoimmunity. Lupus 13, 635-638 (2004).
9. W. Chen, I. Beck, W. Schober, K. Brockow, R. Effner, J. T. M. Buters, H. Behrendt, J. Ring, Human mast cells express androgen receptors but treatment with testosterone exerts no influence on IgE-independent mast cell degranulation elicited by neuromuscular blocking agents. Exp. Dermatol. 19, 302-304 (2010).
10. A. Mantalaris, N. Panoskaltsis, Y. Sakai, P. Bourne, C. Chang, E. M. Messing, J. H. D. Wu, Localization of androgen receptor expression in human bone marrow. J. Pathol. 193, 361-366 (2001).
11. S. M. Viselli, K. R. Reese, J. Fan, W. J. Kovacs, N. J. Olsen, Androgens alter B cell development in normal male mice. Cell. Immunol. 182, 99-104 (1997).
12. J. J. Lai, K. P. Lai, W. Zeng, K. H. Chuang, S. Altuwaijri, C. Chang, Androgen receptor influences on body defense system via modulation of innate and adaptive immune systems: Lessons from conditional AR knockout mice. Am. J. Pathol. 181, 1504-1512 (2012).
13. J. S. Sutherland, G. L. Goldberg, M. V. Hammett, A. P. Uldrich, S. P. Berzins, T. S. Heng, B. R. Blazar, J. L. Millar, M. A. Malin, A. P. Chidgey, R. L. Boyd, Activation of thymic regeneration in mice and humans following androgen blockade. J. Immunol. 175, 2741-2753 (2005).
14. K. Radojević, N. Arsenović-Ranin, D. Kosec, V. Pešić, I. Pilipović, M. Perišić, B. Plećaš-Solarović, G. Leposavić, Neonatal castration affects intrathymic kinetics of T-cell differentiation and the spleen T-cell level. J. Endocrinol. 192, 669-682 (2007).
15. P. O. Gannon, A. O. Poisson, N. Delvoye, R. Lapointe, A.-M. Mes-Masson, F. Saad, Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J. Immunol. Methods 348, 9-17 (2009).
16. M. Mercader, B. K. Bodner, M. T. Moser, P. S. Kwon, E. S. Y. Park, R. G. Manecke, T. M. Ellis, E. M. Wojcik, D. Yang, R. C. Flanigan, W. B. Waters, W. M. Kast, E. D. Kwon, T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc. Natl. Acad. Sci. U.S.A. 98, 14565-14570 (2001).
17. A. C. Roden, M. T. Moser, S. D. Tri, M. Mercader, S. M. Kuntz, H. Dong, A. A. Hurwitz, D. J. McKean, E. Celis, B. C. Leibovich, J. P. Allison, E. D. Kwon, Augmentation of T cell levels and responses induced by androgen deprivation. J. Immunol. 173, 6098-6108 (2004).
18. A. Ardiani, B. Farsaci, C. J. Rogers, A. Protter, Z. Guo, T. H. King, D. Apelian, J. W. Hodge, Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model. Clin. Cancer Res. 19, 6205-6218 (2013).
19. W. R. Foster, B. D. Car, H. Shi, P. C. Levesque, M. T. Obermeier, J. Gan, J. C. Arezzo, S. S. Powlin, J. E. Dinchuk, A. Balog, M. E. Salvati, R. M. Attar, M. M. Gottardis, Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate 71, 480-488 (2011).
20. E. M. Fernández-García, F. E. Vera-Badillo, B. Perez-Valderrama, A. S. Matos-Pita, I. Duran, Immunotherapy in prostate cancer: Review of the current evidence. Clin. Transl. Oncol. 17, 339-357 (2015).
21. S. L. Topalian, F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith, D. F. McDermott, J. D. Powderly, R. D. Carvajal, J. A. Sosman, M. B. Atkins, P. D. Leming, D. R. Spigel, S. J. Antonia, L. Horn, C. G. Drake, D. M. Pardoll, L. Chen, W. H. Sharfman, R. A. Anders, J. M. Taube, T. L. McMiller, H. Xu, A. J. Korman, M. Jure-Kunkel, S. Agrawal, D. McDonald, G. D. Kollia, A. Gupta, J. M. Wigginton, M. Sznol, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
22. P. W. Kantoff, C. S. Higano, N. D. Shore, E. R. Berger, E. J. Small, D. F. Penson, C. H. Redfern, A. C. Ferrari, R. Dreicer, R. B. Sims, Y. Xu, M. W. Frohlich, P. F. Schellhammer; IMPACT Study Investigators, Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422 (2010).
23. P. A. Watson, K. Ellwood-Yen, J. C. King, J. Wongvipat, M. M. Lebeau, C. L. Sawyers, Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. Cancer Res. 65, 11565-11571 (2005).
24. S. Hahn, N. J. Nesslinger, R. J. Drapala, M. Bowden, P. S. Rennie, H. H. Pai, C. Ludgate, B. H. Nelson, Castration induces autoantibody and T cell responses that correlate with inferior outcomes in an androgen-dependent murine tumor model. Int. J. Cancer 125, 2871-2878 (2009).
25. M. Ammirante, J. L. Luo, S. Grivennikov, S. Nedospasov, M. Karin, B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 464, 302-305 (2010).
26. S. Sharma, A. L. Dominguez, D. B. Hoelzinger, J. Lustgarten, CpG-ODN but not other TLR-ligands restore the antitumor responses in old mice: The implications for vaccinations in the aged. Cancer Immunol. Immunother. 57, 549-561 (2008).
27. P. Yu, Y. Lee, Y. Wang, X. Liu, S. Auh, T. F. Gajewski, H. Schreiber, Z. You, C. Kaynor, X. Wang, Y.-X. Fu, Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J. Immunol. 179, 1960-1968 (2007).
28. B. D. Greenstein, F. T. A. Fitzpatrick, M. D. Kendall, M. J. Wheeler, Regeneration of the thymus in old male rats treated with a stable analogue of LHRH. J. Endocrinol. 112, 345-350 (1987).
29. K. F. Windmill, V. W. Lee, Effects of castration on the lymphocytes of the thymus, spleen and lymph nodes. Tissue Cell 30, 104-111 (1998).
30. R. Glaser, J. K. Kiecolt-Glaser, Stress-induced immune dysfunction: Implications for health. Nat. Rev. Immunol. 5, 243-251 (2005).
31. C. A. Smith, G. T. Williams, R. Kingston, E. J. Jenkinson, J. J. T. Owen, Antibodies to CD3/T-cell receptor complex induce death by apoptosis in immature T cells in thymic cultures. Nature 337, 181-184 (1989).
32. + T cells in mice tolerant to Staphylococcus aureus enterotoxin B. Nature 349, 245-248 (1991).
33. R. A. Madan, J. L. Gulley, J. Schlom, S. M. Steinberg, D. J. Liewehr, W. L. Dahut, P. M. Arlen, Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin. Cancer Res. 14, 4526-4531 (2008).
34. N. G. Bowery, D. R. Hill, A. L. Hudson, A. Doble, D. N. Middlemiss, J. Shaw, M. Turnbull, (-)Baclofen decreases neurotransmitter release in the mammalian CNS by an action at a novel GABA receptor. Nature 283, 92-94 (1980).
35. R. Bhat, R. Axtell, A. Mitra, M. Miranda, C. Lock, R. W. Tsien, L. Steinman, Inhibitory role for GABA in autoimmune inflammation. Proc. Natl. Acad. Sci. U.S.A. 107, 2580-2585 (2010).
36. R. Li, K. Evaul, K. K. Sharma, K.-H. Chang, J. Yoshimoto, J. Liu, R. J. Auchus, N. Sharifi, Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: A rationale for increasing drug exposure in castration-resistant prostate cancer. Clin. Cancer Res. 18, 3571-3579 (2012).
37. S. F. Slovin, C. S. Higano, O. Hamid, S. Tejwani, A. Harzstark, J. J. Alumkal, H. I. Scher, K. Chin, P. Gagnier, M. B. McHenry, T. M. Beer, Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: Results from an open-label, multicenter phase I/II study. Ann. Oncol. 24, 1813-1821 (2013).
38. P. R. Womble, P. J. VanVeldhuizen, A. A. Nisbet, G. A. Reed, J. B. Thrasher, J. M. Holzbeierlein, A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients. J. Urol. 186, 882-887 (2011).
39. P. Mathew, L. L. Pisters, C. G. Wood, J. N. Papadopoulos, D. L. Williams, P. F. Thall, S. Wen, E. Horne, C. J. Oborn, R. Langley, I. J. Fidler, C. A. Pettaway, Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer. J. Urol. 181, 81-87; discussion 87 (2009).
40. C. G. Drake, A. D. H. Doody, M. A. Mihalyo, C.-T. Huang, E. Kelleher, S. Ravi, E. L. Hipkiss, D. B. Flies, E. P. Kennedy, M. Long, P. W. McGary, L. Coryell, W. G. Nelson, D. M. Pardoll, A. J. Adler, Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 7, 239-249 (2005).
41. P. M. Arlen, J. L. Gulley, N. Todd, R. Lieberman, S. M. Steinberg, S. Morin, A. Bastian, J. Marte, K.-Y. Tsang, P. Beetham, D. W. Grosenbach, J. Schlom, W. Dahut, Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J. Urol. 174, 539-546 (2005).
42. Y. T. Koh, A. Gray, S. A. Higgins, B. Hubby, W. M. Kast, Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization. Prostate 69, 571-584 (2009).
43. J. Tian, Y. Lu, H. Zhang, C. H. Chau, H. N. Dang, D. L. Kaufman, γ-Aminobutyric acid inhibits T cell autoimmunity and the development of inflammatory responses in a mouse type 1 diabetes model. J. Immunol. 173, 5298-5304 (2004).
44. S. Park, Z. Jiang, E. D. Mortenson, L. Deng, O. Radkevich-Brown, X. Yang, H. Sattar, Y. Wang, N. K. Brown, M. Greene, Y. Liu, J. Tang, S. Wang, Y.-X. Fu, The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 18, 160-170 (2010).
45. E. S. Antonarakis, C G. Drake, Combining immunological and androgen-directed approaches: An emerging concept in prostate cancer immunotherapy. Curr. Opin. Oncol. 24, 258-265 (2012).
46. K. Ellwood-Yen, T. G. Graeber, J. Wongvipat, M. L. Iruela-Arispe, J. Zhang, R. Matusik, G. V. Thomas, C L. Sawyers, Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4, 223-238 (2003).